Despite bruising market, two biotechs price their IPOs while another launches its Nasdaq bid
The current market situation for biotechs is certainly not ideal, but that is not deterring a few companies from diving into the waters of Wall …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
